Pages that link to "Q40708584"

The following pages link to Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. (Q40708584):

Displaying 21 items.

• Drugs acting on SUR1 to treat CNS ischemia and trauma (Q24655850) (← links)
• Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels (Q28253900) (← links)
• Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus (Q33585786) (← links)
• The Sur1-Trpm4 Channel in Spinal Cord Injury (Q33602457) (← links)
• Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes (Q34592210) (← links)
• Sulphonylurea action revisited: the post-cloning era. (Q35159821) (← links)
• Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions (Q35550149) (← links)
• The role of sulphonylureas in the management of type 2 diabetes mellitus (Q35807254) (← links)
• Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury (Q35901019) (← links)
• A review of nateglinide in the management of patients with type 2 diabetes. (Q36596836) (← links)
• Variations in tissue selectivity amongst insulin secretagogues: a systematic review (Q37933466) (← links)
• Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. (Q40464415) (← links)
• Acute and long-term effects of nateglinide on insulin secretory pathways (Q40553689) (← links)
• Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: a mechanistic study (Q42089444) (← links)
• Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis (Q45286060) (← links)
• Impaired glucagon secretory responses in mice lacking the type 1 sulfonylurea receptor (Q46533167) (← links)
• Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. (Q51468978) (← links)
• Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel. (Q52618285) (← links)
• Current literature in diabetes (Q73015854) (← links)
• Mechanism of pharmacochaperoning in a mammalian K channel revealed by cryo-EM (Q83230136) (← links)
• Meglitinides bind ABCC8 (Q112989572) (← links)